Assessing Microchip Technology (MCHP) Valuation After Strong Recent Share Price Momentum

Advertisement

Recent share performance and business snapshot

Microchip Technology (MCHP) has drawn investor attention after a recent share price move, with the stock last closing at $98.05 and posting gains over the past day, week, month and past 3 months.

The company, headquartered in Chandler, Arizona, reports annual revenue of $4,713.1m and net income of $118.8m. It also reports positive annual revenue and net income growth, placing it firmly in the global embedded semiconductor and mixed signal market.

See our latest analysis for Microchip Technology.

The recent 4.94% 1 day share price return sits on top of a 50.78% year to date share price return and a 71.63% 1 year total shareholder return, suggesting that momentum has been building over both short and longer horizons.

If Microchip Technology has caught your eye, this can be a useful moment to widen your watchlist with other semiconductor related opportunities such as 47 AI infrastructure stocks

With Microchip Technology reporting US$4,713.1m in revenue, US$118.8m in net income and a recent run of strong returns, the key question is simple: is the stock undervalued or is the market already pricing in future growth?

Most Popular Narrative: 13.1% Overvalued

The most followed narrative currently values Microchip Technology at $86.67 per share, which sits below the recent $98.05 close and presents the stock as pricing in a lot of future progress.

Microchip is experiencing a broad-based recovery in key end-markets, such as industrial, automotive, data center, and defense, following a prolonged period of inventory correction. Management believes shipments remain below normalized end demand, which they see as setting up for continued above-seasonal revenue growth as inventories are replenished over the coming quarters.

Read the complete narrative.

The narrative explores what would need to occur for that valuation to make sense and emphasizes faster revenue, larger margins, and a future earnings profile that is very different from today.

Result: Fair Value of $86.67 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still watchpoints here, including elevated inventory pressures and substantial debt that could limit margins, cash flow flexibility, and support for the current valuation narrative.

Find out about the key risks to this Microchip Technology narrative.

Next Steps

With sentiment split between risk and reward, this is a moment to move quickly, review the underlying data carefully, and form your own view using 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop here, you could miss stocks that better match your goals, so take a few minutes to scan these targeted ideas and sharpen your shortlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:MCHP

Microchip Technology

Develops, manufactures, and sells smart, connected, and secure embedded control solutions in the Americas, Europe, and Asia.

High growth potential and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
51 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4849.2% undervalued
205 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43038.1% undervalued
9 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9956.4% undervalued
13 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

ON
LOT logo
Ontological on Lotus Technology ·

Lotus Tech, Finloop and FOMO Pay Collaborate to Explore Vehicle Tokenization

Fair Value:US$2.463.9% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
NE
AIIO logo
newsfinder11221 on Robo.ai ·

Robo.ai (NASDAQ: AIIO): Building the Infrastructure Behind the AI Revolution

Fair Value:US$540.4% undervalued
1 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
ALMIN logo
European_Hidden_Gem_Stocks on MINT Société anonyme ·

Mint SA: A French Micro-Cap Energy Retailer Worth Watching

Fair Value:€1153.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
88 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
199 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
73 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0